Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

NCT01835236 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT01835236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01835236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2013
Completion date
May 26, 2020
Enrollment
208 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer